期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性阻塞性肺疾病患者诱导痰中细胞因子HMGB1的变化及临床意义 被引量：6

下载PDF
导出
摘要 目的探讨HMGB1在慢性阻塞性肺疾病(COPD)发病中的作用及其与肺功能的相关性。方法按标准纳入COPD患者56例,健康对照组30例,收集研究对象的基本资料,并在治疗前后对各组进行肺功能检测,行诱导痰中中性粒细胞计数,用ELISA法检测各组诱导痰中HMGB1的表达水平。结果①治疗前COPD组诱导痰中的HMGBl含量及中性粒细胞水平高于健康对照组(P<0.01),急性加重期诱导痰中HMGBl的含量及中性粒细胞水平高于稳定期(P<0.01),治疗后诱导痰中的HMGBl的含量及中性粒细胞水平均较治疗前明显下降(P<0.01),极重度和重度COPD患者诱导痰的HMGBl表达比轻中度COPD患者增高(P<0.01)。②治疗前后COPD患者诱导痰HMGBl浓度与肺功能参数(FEV1%、FEV1/FVC)均呈显著负相关(r<0且P<0.01),与中性粒细胞水平呈正相关(r>0且P<0.01)。结论 HMGBl促进COPD的发生和发展,且诱导痰中HMGB1水平与COPD严重程度有关。
作者 代灵灵 程哲 康燕 李芳
机构地区 郑州大学第一附属医院呼吸与危重症医学二科河南省高等学校临床医学重点学科开放实验室
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第5期896-898,共3页 Chinese Journal of Gerontology
基金 河南省卫生科技创新型人才工程(豫卫科2010-52) 郑州大学第一附属医院青年基金项目
关键词 COPD HMGB1 肺功能 中性粒细胞
分类号 R563 [医药卫生—呼吸系统]
  • 相关文献

参考文献11

  • 1Moermans C,Heinen V,Nquyen M,et al.Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease [J].Cytokine,2011 ;56(2):298-304.
  • 2Switalla S,Lauenstein L,Prenzler F,et al.Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices[J].Toxicol Appl Pharmacol,2010:Epub ahead of print.
  • 3Paggiaro PL,Chanez P,Holz O,et al.Sputum induction[J].Eur Respir J Suppl,2002 ;37:3S-8S.
  • 4Pavord ID,Pizzichini MM,Pizzichini E,et al.The use of induced sputum to investigate airway inflammation [J].Thorax,1997 ;52:498-501.
  • 5Wang H,Bloom O,Zhang M,et al.HMG-1 as a late mediator of endotoxin lethality in mice[J].Science,1999 ;285(5425):248-51.
  • 6Abraham E,Arcaoli J,Carmody A,et al.HMG-1 as a mediator of lung inflammation[J].J Immunol,2000;165 (6):2950-4.
  • 7Taniguchi N,Kawahara K,Yone K,et al.High mobility group box Chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine[J].Arthritis Rheum,2003 ;48(4):971-81.
  • 8程哲,代灵灵,曹德飞,吴秋歌,宋永娜,康燕,夏杰,司纪明,陈春艳.支气管哮喘患者诱导痰中HMGBl和RAGE水平的变化及临床意义[J].中华医学杂志,2011,91(22):1538-1542. 被引量：10
  • 9Wang H,Li W,Goldstein R,et al.HMGB 1 as a potential therapeutic Targe [J].Novartis Found Symp,2007 ;280:73- 85.
  • 10Ferhani N,Letuve S,Kozhich A,et al.Expression of high-mobility group boxl and of receptor for advanced glycation end Products in chronic obstructive pulmonary[J].Am J Respir Crit Care Med,2010; 181(9):917-27.

二级参考文献16

  • 1Green RH,Brightling CE,Woltmann G,et al.Analysis of induced sputum in adults with asthma:identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids.Thorax,2002,57:875-879.
  • 2Watanabe T,Asai K,Fujimoto H,et al.Increased levels of HMGB-1 and endogenous secretory RAGE in induced sputum from asthmatic patients.Respir Med,2011,105:519-525.
  • 3Paggiaro PL,Chanez P,Holz O,et al.Sputum induction.Eur Respir J Suppl,2002,37:3S-8S.
  • 4Pavord ID,Pizzichini MM,Pizzichini E,et al.The use of induced sputum to investigate airway inflammation.Thorax,1997,52:498-501.
  • 5Baines KJ,Simpson JL,Bowden NA,et al.Differential gene expression and cytokine production from neutrophils in asthma phenotypes.Eur Respir J,2010,35:522-531.
  • 6Wang H,Bloom O,Zhang M,et al.HMG-1 as a late mediator of endotoxin lethality in mice.Science,1999,285:248-251.
  • 7Lotze MT,Zeh HJ,Rubartelli A,et al.The grateful dead:damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.Immunol Rev,2007,220:60-81.
  • 8Park JS,Gamboni-Robertson F,He Q,et al.High mobility group box 1 protein interacts with multiple Toll-like receptors.Am J Physiol Cell Physiol,2006,290:C917-C924.
  • 9Tian J,Avalos AM,Mao SY,et al.Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.Nat Immunol,2007,8:487-496.
  • 10Palumbo R,Galvez BG,Pusteria T,et al.Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation.J Cell Biol,2007,179:33-40.

共引文献9

同被引文献66

  • 1慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志（电子版）,2014,6(2):67-80. 被引量：2049
  • 2王轩,韩春凤,陈志诚.乌司他丁联合血必净治疗慢性阻塞性肺病急性加重期合并呼吸衰竭的疗效[J].中国老年学杂志,2014,34(11):3157-3158. 被引量：18
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量：1795
  • 4Vestbo J, Hurd SS, Agust i AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med, 2013,187(4):347-365.
  • 5Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J, 2008,31(2):416-469.
  • 6Koutsokera A, Loukides S, Gourgoulianis KI, et aL Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem, 2008,15(6):620-630.
  • 7Antus B, Barta I, Horvath I, et al. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology, 2010,15(3): 472-477.
  • 8Antus B, Barta I, Kullmann T, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive puhnonary disease: a longitudinal study. Am J Respir Crit Care Med, 2010,182(12):1492-1497.
  • 9Tateosian NL, Costa MJ, Guerrieri D, et al. Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients. Cytokine, 2012,58(3):361-367.
  • 10Antczak A, Ciebiada M, Pietras T, et al. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci, 2012,8(2):277-285.

引证文献6

二级引证文献42

中国老年学杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部